natgillin/translations-raw huggingface dataset:
cyclizing the above compound of formula IVa to obtain a compound of formula Va in the form of diastereoisomeric mixture (S,R+R,R) 
' kojoj je Y gore definiran; cikliziranje gore navedenog spoja formule IVa, da bi se dobio spoj formule Va u obliku dijastereoizomerne smjese (S, R+R, R)
before receiving in said apparatus a bag, obtaining from said coded-identification means the data concerning the blood contained in the bag and storing them in a memory, exchanging the data concerning the blood contained in the bag with a data-management system external to said apparatus, and 
- prije preuzimanja u navedeni uređaj (1) ili vađenja iz njega vrećice, dobivanje iz sustava za kodiranu identifikaciju podataka koji se odnose na krv koja je sadržana u vrećici i pohranjivanje tih podataka u memoriju. naznačen time što nadalje sadržava fazu:
In another embodiment, the antibody or antigen binding fragment thereof further comprises a human IgG4 constant region, and a human k light chain constant region. 
Protutijelo ili njegov ulomak koji veže antigen za uporabu prema bilo kojem od zahtjeva 1-3, naznačen time što protutijelo ili njegov ulomak koji veže antigen nadalje sadrži human IgG4 konstantnu regiju, i humanu K konstantnu regiju lakog lanca.
The monoclonal antibody or antigen binding fragment thereof of claim 1, which is produced by hybridoma cell line 3C12F, 7D1G, 7D12A, 18V4F or 18P7E or which competitively blocks binding of an antibody produced by hybridoma cell line 3C12F, 7D1G, 7D12A, 18V4F or 18P7E, wherein 
Monoklonsko protutijelo, ili njegov fragment koji veže antigen, u skladu s patentnim zahtjevom 1, naznačeno time, da je proizveden od hibridne stanične linije, 3C12F, 7DIG, 7D12A, I8V4F ili 18P7E ili koji kompetitivno blokira vezanje protutijela kojeg proizvodi hibridna stanična linija 3C12F, 7D1G, 7DI2A, 18V4F ili 18P7E, pri čemu je
A method for killing a pathogenic organism or inhibiting the growth and/or reproduction of a pathogenic organism comprising contacting the pathogenic organism with a molecule of the following structure: (X2i-1-Yi-X2i-Zi)n, wherein: 
Postupak za ubijanje patogenog organizma ili inhibiciju rasta i / ili reprodukcije patogenog organizma, naznačen time, da obuhvaća kontaktiranje patogenog organizma s molekulom slijedeće strukture: (Xo;-1-Yi-X2-Zi)o Pri čemu:
treating a compound of formula (2a): 
(a) obradu spoja sa formulom (2):
the compound of formula (XVII) is subjected to a condensation reaction with an amine RbNH2, Rb and Rb' being as defined in Claim 1. 
spoj s formulom (XVII) se podvrgava reakciji kondenzacije s aminom RbNH2, Rb i Rb' je kako je definirano u zahtjevu 1.
an antisense oligomer comprising the nucleotide sequence shown by any one of the SEQ ID NOS: 7, 8 or 9; 
antisensni oligomer koji sadrži nukleotidnu sekvencu SEQ ID NO: 1 ili 2;
A method according to claim 7 or 8, wherein the protomers are homologous or heterologous with respect to the monomers. 
Postupak u skladu s patentnim zahtjevom 7 ili 8, naznačen time, da su protomeri homologni ili heterologni u odnosu na monomere.
The composition of claim 19, wherein the avermectin or milbemycin is abamectin, dimadectin, doramectin, emamectin, eprinomectin, ivermectin, latidectin, lepimectin, selamectin, milbemectin, milbemycin D, milbemycin 5-oxime, moxidectin or nemadectin. 
Veterinarski ili agrikulturni sastav prema zahtjevu 31, naznačen time, da je avermektin ili milbemicin odabran iz skupine koja se sastoji od sljedećih: abamektin, dimadektin, doramektin, emamektin, eprinomektin, ivermektin, latidektin, lepimektin, selamektin, milbemektin, milbemicin D, moksidektin i nemadektin.
• is either free of amino acids or comprises one or more amino acids in a (collective) concentration of at most 0.1 mM; and 
* ne sadrži aminokiseline 1li sadrži jednu 1li više aminokiselina u (zajedničkoj) koncentraciji do najviše 0.1 mM: i
The fusion protein of any one of claims 1 to 5, wherein the nuclear hormone receptor is selected from the group consisting of an estrogen receptor, a progesterone receptor, a glucocorticoid receptor, an androgen receptor and a functionally active variant thereof, particularly an estrogen receptor or a functionally active variant thereof. 
gdje receptor jest nuklearni hormonski receptor od sisavca ili humani, izabran iz grupe koja obuhvaća Estrogenski receptor, progesteronski receptor, glukokortikoidni receptor, androgeni receptor i mutant ER(T2) Estrogenskog receptora definirano u SEQ ID NO: 80.
The door according to claim 2, wherein said lower end door portion (30) moves upwardly when said lower end door portion (30) receives an upward thrust as a result of a lifting of a floor below said lower end door portion. 
Vrata u skladu s patentnim zahtjevom 3, naznačena time što se navedeni donji dio vrata (30) pomakne prema gore kada primi udarac u tom smjeru kao posljedicu podizanja poda.
Het represents a group of formula 
Het predstavlja skupinu formule
Z-C(RD7)(RD8)(RD9) (substituent group C, RD7, RD8, RD9, and Z are same as claim 13). 
(Supstituentska skupina C, R"", R"%, R"', i Z, imaju isto značenje kao što su navedeni u zahtjevu 13).
0.04 gram of roflumilast is added, and the mixture is stirred until a clear solution is obtained. 
Doda se 0.04 grama roflumilasta i smjesa se miješa do dobivanja bistre otopine.
is C1-C4 linear alkyl or C3-C4 branched alkyl; or a pharmaceutically acceptable salt thereof. 
R* je Ci-Ca nerazgranati alkil ili Cz-Ca razgranati alkil; ili njegova farmaceutski prihvatljiva sol.
The mixture was extracted with ethyl acetate. 
Ovu smjesu ekstrahira se etil-acetatom.
inserting the metal substrate into the plating solution; and performing an electroplating process to coat the metal substrate on all sides with a metal layer, wherein the metal layer contains embedded luminescent particles from the plating solution, wherein the electroplating process includes a rotating barrel in which the metal substrate is contained when inserted into the plating solution, wherein tumbling from the process deposits the luminescent particles in the metal layer that is formed during the electroplating process such that the luminescent particles are physically distributed throughout the entirety of the metal layer and a portion of the luminescent particles are embedded on or near an outer-most surface of the metal layer in a manner to be detectable by UV, visible or infrared light. 
PATENTNI ZAHTJEVI Postupak deponiranje metalnog sloja s uklopljenim luminiscentnim česticama na metalnu podlogu, koji se sastoji u: miješanju luminiscentnih čestica s metalnim materijalom kako bi se dobilo otopinu za galvaniziranje; stavljanju metalne podloge u otopinu za galvaniziranje; i provođenju postupka oblaganja kako bi se obložilo metalnu podlogu metalnim slojem, gdje metalni sloj sadrži uklopljene luminiscentne čestice, gdje je postupak oblaganja postupak galvaniziranja i naznačen time što postupak galvaniziranja uključuje rotiranje bubnja u kojem se nalazi metalna podloga kada se stavi u otopinu za galvaniziranje; gdje se luminiscentne čestice dispergirane u otopini za galvaniziranje fizički raspodijele po cijelom metalnom matriksu prilikom formiranja galvaniziranog sloja.
The receiver unit is shown in Figure 2 In the embodiment shown, the receiver is housed in a plastic container. 
Jedinica prijemnika je prikazana na slici 2. U prikazanoj izvedbi, prijemnik je smješten u plastično kućište.
The method of claim 10, wherein said capture step utilizes cation exchange chromatography (CEX), hydrophobic charge induction chromatography (HCIC), or mixed mode chromatography. 
Postupak u skladu s patentnim zahtjevom 6, naznačen time što navedeni korak uhvata upotrebljava kationskoizmjenjivačku kromatografiju (CEX), kromatografiju s hidrofobno induciranim nabojem (HCIC), ili kromatografiju s miješanim načinom rada.
The method according to claim 2, wherein said inflammatory bowel disease is selected from the group consisting of Crohn's disease and ulcerative colitis. 
Farmaceutski pripravak za uporabu prema zahtjevu 18, gdje je navedena upalna bolest crijeva izabrana iz skupine koja se sastoji od Kronove bolesti i ulceroznog kolitisa.
which comprises reacting a compound of the formula IV with an acid chloride of the formula VI in the presence of a base A providing the ester of the formula VII; wherein in the compounds of the formulae IV and VI R1 and R2 are each as defined in formula VII. 
R2 je metoksi, OCH2C4Hs, F, Cl, Br ili OCH,CH,CH,N(CH2CHCHLCH2),; i njegove soli; naznačen time što se sastoji u reakciji spoja formule IV s kiselinskim kloridom formule VI, u prisutnosti baze A, čime se dobije ester formule VII: gdje je u spojevima formula IV i VI svaki od R1 i R2 definiran kao u formuli VII.
alternatively, R4 and R5 are taken together with the atom to which they are bound to form a ring structure selected from the group consisting of 2-(2,5-dihydro-furanyl) and 2-tetrahydrofuranyl; or a pharmaceutically acceptable salt thereof. 
Alternativno, R* i R* su uzeti zajedno s atomom na koji su vezani da formiraju 2- [1,3] dioksolanil; ili njihovu farmaceutski prihvatljivu sol.
The tetrahydrofuran is removed in vacuo, diethyl ether is added and the aqueous portion is extracted. 
Tetrahidrofuran se ukloni u vakuumu, doda se dietil-eter, a vodeni dio ekstrahira.
The displacement of closure (112) from the normally closed position to an open position that enables the dispensing of a pill from storage chamber (104) is preferably actuated by the mouth of the user when interacting with spout outlet (106), as described further herein below. 
što se pomicanje navedenog odvojivog hermetičkog zatvarača (112; 212; 412; 512) iz navedenog zatvorenog položaja kako bi se omogućilo izdavanje najmanje jedne pilule iz navedene komore (104; 204; 404), pokreće jednim od sljedećih -
The humanized CD37-specific binding protein according to claim 6, wherein the immunoglobulin hinge region polypeptide can be an IgG1, IgA or IgE hinge region polypeptide or a mutant IgG1. 
Humanizirani CD37-specifični vezni protein u skladu s patentnim zahtjevom 6, pri čemu polipeptid zglobne regije imunoglobulina može biti polipeptid zglobne regije IgG1, IgA ili IgE ili mutirani IgG1.
Suitable inorganic acids include hydrochloric, hydrobromic, sulfuric, phosphoric, and nitric acids. 
Pogodne anorganske kiseline uključuju klorovodičnu, bromovodičnu, sumpornu, fosfornu, te dušičnu kiselinu.
A compound having the formula wherein R1 is selected from the group consisting of halo, C1-6 alkyl, cyano, and trihalomethyl; each R2 is independently hydrogen, trihalomethyl, carboxylate, an amide, or a sulfonyl group; and n is 1 or 2, provided that when n is 1, R2 is not hydrogen, and when n is 2, both R2 groups are not hydrogen; 
(i naznačen time da je Ry odabran iz skupine koja se sastoji od halo, C;.g alkila, cijano, i trihalometila; svaki pojedini R> je neovisno vodik, trihalometil, karboksilat, amid, ili sulfonil skupina; a n je 1 ili 2, pod uvjetom da kada n je 1, R2 nije vodik, a kada n je 2, obje R» skupine nisu vodik; 10
A compound of any one of aspects 1-32, or a pharmaceutically acceptable salt, hydrate, solvate or crystalline form thereof, for use in treating a viral disease in a subject, wherein the viral disease is selected from the group consisting of human papilloma virus, HIV, hepatitis B virus, hepatitis C virus, variola virus, vaccinia virus, an adenovirus, a cytomegalovirus, herpes simplex virus 1, herpes simplex virus 2, Epstein Barr virus, BK virus, JC virus, feline leukemia virus and feline immunodeficiency virus. 
Spoj prema bilo kojem zahtjevu od 1 do 7 ili njegova farmaceutski prihvatljiva sol, za primjenu u liječenju virusnog oboljenja kod ispitanika, naznačen time, što je virusno oboljenje odabrano iz skupine koja se sastoji od ljudskog papilomavorusa, HIV-a, virusa hepatitisa B, virusa hepatitisa C, virusa boginja, virusa kravljih boginja, HR P20181871 T1 adenovirusa, citomegalovirusa, virusa herpesa simpleksa 1, virusa herpesa simpleksa 2, Epstein Barrovog virusa, BK virusa, JC virusa, cervikalne intraepitelne neoplazije, analne intraepitelne neoplazije i vulvarne intraepitelne neoplazije, virusa mačje leukemije i virusa mačje imunodeficijencije.
Process according to any one of the preceding claims, characterized in that above or below or between pieces of wood (10) at least one plane, preferably board-like piece (10) of another wood type is arranged, wherein preferably said material pieces are glued to adjoining pieces of wood or pieces of material. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time, što se postavi iznad ili ispod ili između komada od drva (10) najmanje jedan ravan komad, za koji je povoljno da ima oblik ploče (10), jedne druge HR P20070484 T3 vrste drva, pri čemu je poželjno da su komadi od navedenog materijala zalijepljeni na susjedne komade od drva ili na komade od drugog materijala.
The polypeptide for use according to any one of claims 1-4, wherein the polypeptide is an ActRII-Fc fusion protein comprising an amino acid sequence selected from: 
ActRII-Fc fuzijski protein za uporabu u liječenju ili prevenciji anemije kod humanog pacijenta kod kojeg postoji potreba za tim, pri čemu ActRII-Fc fuzijski protein sadrži aminokiselinsku sekvencu koja je izabrana iz grupe koju čine:
The antibody of any one of claims 1-17 which comprises a combination of heavy chains and light chains selected from the following possibilities (i) to (ix): 
Monoklonsko protutijelo koje sadrži alotipsku modifikaciju u teškom lancu protutijela, pri čemu protutijelo sadrži kombinaciju teških lanaca i lakih lanaca odabranu iz slijedećih mogućnosti (i) do (ix):
a B-Raf inhibitor of the formula or a pharmaceutically acceptable salt thereof, 
inhibitora B-Raf s formulom ili njegove farmaceutski prihvatljive soli,
A compound of claim 2 or pharmaceutically acceptable salts thereof wherein A is a nitrogen-containing 6-membered heterocycloalkyl wherein said heterocycloalkyl is piperidine and is attached to the ring N of the piperidine, and m is zero. 
S C R3 je vezan na N u prstenu pirolidina, a m je nula. Spoj u skladu s patentnim zahtjevom 2, ili njegove farmaceutski prihvatljive soli, naznačen time što je A 6-eročlani heterocikloalkil koji sadrži dušik gdje je navedeni heterocikloalkil piperidin, 1
granulating the materials from the step (2) using a dry granulation process or a wet granulation process, wherein the dry granulation process comprises: delumping an intragranular lubricant using a screen or mill; adding the intragranular lubricant to the blend from the step (2) and blending to form a lubricated blend; 
granulacije materijala iz koraka (2) korištenjem postupka suhe granulacije koji obuhvaća: uklanjanje grudica iz intragranularnog lubrikanta upotrebom pogodnog sita ili mlina; dodavanje lubrikanta smjesi iz koraka (2) i miješanje;
The cake is taken out of the oven and unmoulded. 
Kolač izvaditi iz pećnice 1 1z kalupa.
The dosage form of any of the preceding claims, which comprises, relative to the weight of the dosage form, from 5 to 30 % by weight of said HIV protease inhibitor, from 2 to 20 % by weight of said surfactant, and from 0 to 15 % by weight of additives. 
Dozirni oblik prema bilo kojem od prethodnih zahtjeva, koji sadrži, u odnosu na težinu dozirnog oblika, od 5 do 30% težine inhibitora proteaze HIV-a, od 2 do 20% težine surfaktanta i od 0 do 15% težine aditiva.
The method as in embodiment 13, wherein the liquid substance is applied with a Piezo ink head. 
Postupak prema zahtjevu 11, naznačen time što se tekuća supstanca primjenjuje s glavom za Piezo tintu ili glavom za termo tintu.
A compound according to claim 1 having the structure or a pharmaceutically acceptable salt or solvate thereof. 
Spoj u skladu s patentnim zahtjevom 1, sa strukturom ro ili njegova farmaceutski prihvatljiva sol ili solvat, 27.
The compound for use of claim 1, wherein the disease or disorder is small bowel cancer. 
Spoj ili sastav za uporabu prema zahtjevu 3, naznačen time, da bolest ili poremećaj je karcinom jajnika.
Preferably, the hydrophobic charge-induction step is carried out on a 4-mercapto-ethyl-pyridine (MEP) resin. 
Poželjno, korak koji obuhvaća hidrofobnu indukciju naboja se provodi na nosaču 4-merkapto-etil-piridinu (MEP).
In particular said X-ray powder diffraction pattern comprises peaks at 4.99, 20.28, 21.14, 21.64 and 23.23 degrees 2Θ (±0.1 degrees 2Θ), wherein said X-ray powder diffraction pattern is made using CuKa1 radiation. 
Postupak prema zahtjevu 1, naznačen time, da uzorak difrakcije praha X-zraka nadalje obuhvaća vršne vrijednosti na 4,99 i 23,23 stupnja 20 (+ 0,1 stupanj 20), pri čemu se navedeni uzorak difrakcije praha X-zraka dobiva uporabom CuK.,-radijacije.
13) or a derivative or mutant thereof, whereby said derivative is a polypeptide molecule which is at least 70% identical in sequence with the original CERT sequence or its complementary sequence or said derivative is a homologous CERT sequence from a different organism and whereby said mutant is based on targeted modification of CERT sequences by substitution, insertion or deletion of one to ten amino acids. 
13) ili njegov derivat ili njegov mutant, pri čemu spomenuti derivat je polipeptidna molekula, čija sekvenca je barem 70% istovjetna originalnoj CERT-sekvenci ili njezinoj komplementarnoj sekvenci ili je spomenuti derivat homologna CERT-sekvenca iz različitog organizma, te pri čemu se spomenuti mutant bazira na ciljanoj modifikaciji CERT-sekvenci pomoću zamjene, umetanja ili izbacivanja od jedne do deset amino kiselina.
A use of the combination of claim 1 to impart at least a malty-chocolate-honey-butter-cream flavour and aroma to a milk source. 
Upotreba kombinacije u skladu s patentnim zahtjevom 1, naznačena time što je kombinacija namijenjena dodavanju u najmanju ruku mirisa i aroma slada-čokolade-meda-maslaca-vrhnja izvoru mlijeka.
the mouse comprises a B cell that expresses an antibody that specifically binds an antigen of interest, wherein the antibody comprises said common light chain and an immunoglobulin heavy chain derived from a rearrangement of human immunoglobulin heavy chain variable (VH) gene segments selected from the group consisting of a VH2-5, VH3-23, VH3-30, VH4-59, and VH5-51 gene segment; and 
(c) miš sadržava B-stanicu koja eksprimira protutijelo koje se specifično veže na antigen od interesa, pri čemu protutijelo sadržava navedeni zajednički laki lanac 1 teški lanac imunoglobulina dobivene preuređenjem genskih odsječaka varijabilne regije teškog lanca o (Vag) humanog imunoglobulina odabranih iz skupine koja se sastoji od odsječaka gena Vr2-5, Vu3-23, Vr3-30, Vu4-59 i Vn5-51 1
reacting sulfamic acid and an amine to form an amidosulfamic acid salt; and reacting the amidosulfamic acid salt and acetoacetylating agent to form the acetoacetamide salt. 
reakciju sulfaminske kiseline s aminom, u svrhu tvorbe amidosulfaminske kiselinske soli; i reakciju amidosulfaminske kiselinske soli s acetoacetilacijskim sredstvom u svrhu tvorbe acetoacetamidne soli.
A compound according to claim 1 selected from the group consisting of 
Spoj prema zahtjevu 1, naznačen time, da je odabran iz skupine koju čine:
The common characteristics of these systems is that they can not be designed like a book with the ability to open with an angle of more than 180°, preferably 240° due to the characteristics of i.a. the metal material and thus cannot be packed in the automated packing machines. 
Zajednička karakteristika ovih sustava je ta, da oni ne mogu biti izvedeni kao knjiga s mogućnošću da se otvore pod kutom koji je veći od 180", poželjno 240%, zbog karakteristika koje ima metalni materijal i tako ne mogu biti pakirani u automatiziranim strojevima za pakiranje.
Use of the humanized anti-a2 integrin antibody according to any one of claims 1-16 for the preparation of a medicament for the treatment of an a2B1 integrin-associated disorder selected from inflammatory disease, autoimmune disease, a disease associated with abnormal or higher than normal angiogenesis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, reactions to transplant, optical neuritis, spinal cord trauma, rheumatoid arthritis, systemic lupus erythematosus (SLE), diabetes mellitus, multiple sclerosis, Reynaud's syndrome, experimental autoimmune encephalomyelitis, Sjorgen's syndrome, scleroderma, juvenile onset diabetes, diabetic retinopathy, age related macular degeneration, cardiovascular disease, psoriasis, cancer as well as infections that induce an inflammatory response. 
Uporaba humaniziranog anti-a2 integrin protutijela prema bilo kojem od zahtjeva 1-16 za pripremu lijeka za liječenje poremećaja povezanog s a2B1 integrinom, izabranog između inflamatorne bolesti, autoimune bolesti, bolesti povezane s abnormalnom ili povećanom angiogenezom, inflamatorne bolesti crijeva, Crohnove bolesti, ulceroznog kolitisa, reakcije na transplantat, optičkog neuritisa, traume leđne moždine, reumatoidnog artritisa, sistemskog eritematoznog lupusa (SLE), šećerne bolesti, multiple skleroze, Reynaudovog sindroma, eksperimentalnog autoimunog encefalomijelitisa, Sjorgenovog sindroma, skleroderme, juvenilnog dijabetesa, dijabetičke retinopatije, makularne degeneracije povezane sa starenjem, kardiovaskularne bolesti, psorijaze, raka kao i infekcija koje induciraju inflamatorni odgovor.
A treatment effective amount of an anti-Alzheimers disease active agent for use as in claim 6 or claim 7, wherein said genetic variant of the TOMM40 gene is a poly-T insertion variant at genomic location 50,094,889 of NBCI Build 36.3 (rs10524523). 
Liječenje s učinkovitom količinom djelotvornog sredstva protiv Alzheimerove bolesti, za uporabu prema zahtjevu 6 ili zahtjevu 7, naznačeno time, da navedena genetička varijanta od TOMM40-gena je poli-T umetnuta varijanta na genomskom mjestu 50,094,889 od NBCI-Build 36.3 (rs10524523).
According to some embodiments of the present invention, the fiber cement product may be a fiber cement plate having at least one surface comprising at least one groove. 
Postupak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time što vlaknasti cementni proizvod je ploča od vlaknastog cementa koja ima najmanje jednu površinu koja sadrži najmanje jedan utor.
a step of the sentinel receiving geolocation data; 
- korak prijema (EM3) od strane kućišta (10) geolokacijskih podataka;
A compound according to claim 10 or a pharmacologically acceptable salt thereof, wherein R8b represents a C1-C4 alkyl group. 
Spoj prema zahtjevu 10 ili njegova farmakološki prikladna sol, gdje R* predstavlja C,-C, alkil skupinu.
The fire-resistant pane according to claim 1, wherein the second sublayer contains tin-zinc oxide and wherein a ratio of zinc:tin ranges from 5 wt. %:95 wt. % to 95 wt. %:5 wt. %. 
Vatrootporni panel (10) u skladu s patentnim zahtjevom 5, naznačen time, da njegov zaštitni sloj (3.1) sadrži kositar-cinkov oksid naznačen time daje omjer cinka: raspon kositra od 5 wt.%: 95 wt.% do 95 wt.%:5 wt.% i poželjno od 15 wt.%: 85 wt.% do 70 wt.%: 30 wt.%.